Yabao Pharmaceutical Group Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Ren Wei

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Yabao Pharmaceutical Group's (SHSE:600351) Strong Earnings Are Of Good Quality

May 02

Geschäftsführer

Ren Wei (38 yo)

no data

Amtszeit

CN¥1,573,800

Vergütung

Mr. Ren Wei serves as General Manager and Vice Chairman at Yabao Pharmaceutical Group Co., Ltd and served as its Deputy General Manager. Mr. Wei served as General manager in Beijing Yabao Investment Manage...

Yabao Pharmaceutical Group Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Yabao Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.094 (vs CN¥0.079 in 2Q 2023)

Yabao Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 15, 2024

Yabao Pharmaceutical Group's (SHSE:600351) Strong Earnings Are Of Good Quality

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 1Q 2023)

Yabao Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Yabao Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Yabao Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.008 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.079 (vs CN¥0.038 in 2Q 2022)

Yabao Pharmaceutical Group Co., Ltd (SHSE:600351) commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.

First quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.093 in 1Q 2022)

Investor sentiment deteriorated over the past week

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.038 (vs CN¥0.045 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.045 (vs CN¥0.027 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.084 (vs CN¥0.052 in 1Q 2020)

New 90-day low: CN¥4.58

New 90-day low: CN¥4.60

New 90-day low: CN¥4.99

New 90-day low: CN¥5.09

New 90-day low: CN¥5.25

Third quarter earnings released

Yabao Pharmaceutical Group Co., Ltd to Report Q3, 2020 Results on Oct 24, 2020

Earnings released

New 90-day high - CN¥5.73

Yabao Pharmaceutical Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Geschäftsführer

Amtszeit

Vergütung